Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 2/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266091 | 0.83 | MAPT (0.70) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL2264663 | 0.83 | MAPT (0.56) | MAPTKDM4EALDH1A1APEX1RECQL | |
| Iodide SCHEMBL11586547 | 0.81 | MAPT (0.54) | MAPTKDM4EALDH1A1APEX1RECQL | |
| Bromide SCHEMBL11352026 | 0.81 | MAPT (0.54) | MAPTKDM4EALDH1A1APEX1RECQL | |
| Hydrochloric Acid SCHEMBL11587377 | 0.81 | MAPT (0.54) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL30490133 | 0.78 | MAPT (0.63) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL14154810 | 0.78 | MAPT (0.63) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL3925343 | 0.76 | MAPT (0.48) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL12113061 | 0.76 | MAPT (0.61) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL31153163 | 0.76 | MAPT (0.61) | MAPTKDM4EALDH1A1APEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888579-B1 | NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | AVENTIS PHARMA SA (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | MAPT 844/4885KDM4E 3419/4885ALDH1A1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.